Skip to main content

Research Repository

Advanced Search

All Outputs (11)

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. (2019)
Journal Article
Yiu, Z., Mason, K., Barker, J., Hampton, P., McElhone, K., Smith, C., …Burden, A. (in press). A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. British Journal of Dermatology, 181(6), 1265 - 1271. https://doi.org/10.1111/bjd.17849

BACKGROUND: Patients recruited in randomized controlled trials (RCTs) for biologic therapies in psoriasis are not fully representative of the real-world psoriasis population. OBJECTIVES: Firstly, to investigate whether patient characteristics are ass... Read More about A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis..

Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis (2019)
Journal Article
Tsakok, T., Wilson, N., Dand, N., Loeff, F. C., Bloem, K., Baudry, D., …for the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR) Study Group and the Psoriasis Stratification to Optimise Relevant Therapy (PSORT) Consortium. (2019). Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. JAMA Dermatology, 155(11), 1235. https://doi.org/10.1001/jamadermatol.2019.1783

Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2019)
Journal Article
Rungapiromnan, W., Mason, K., Lunt, M., McElhone, K., Burden, A., Rutter, M., …Study Group, B. (2020). Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Pharmacoepidemiology and Drug Safety, 34(4), 467 - 467. https://doi.org/10.1111/jdv.16018

Background
The cardiovascular safety profile of biologic therapies used for psoriasis is unclear.

Objectives
To compare the risk of major cardiovascular events (CVE s; acute coronary syndrome, unstable angina, myocardial infarction and stroke) i... Read More about Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. (2019)
Journal Article
Rungapiromnan, W., Mason, K., Lunt, M., McElhone, K., Burden, A., Rutter, M., …Study Group, B. (2019). Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 34(4), 769 - 778. https://doi.org/10.1111/jdv.16018

BACKGROUND: The cardiovascular safety profile of biologic therapies used for psoriasis is unclear. OBJECTIVES: To compare the risk of major cardiovascular events (CVEs; acute coronary syndrome, unstable angina, myocardial infarction and stroke) in pa... Read More about Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study..

Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. (2019)
Journal Article
Mason, K., Williams, S., Yiu, Z., McElhone, K., Ashcroft, D., Kleyn, C., …Griffiths, C. (2019). Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. British Journal of Dermatology, 181(2), 256 - 264. https://doi.org/10.1111/bjd.17625

BACKGROUND: The persistence and effectiveness of systemic therapies for moderate-to-severe psoriasis in current clinical practice are poorly characterized. OBJECTIVES: To systematically review observational studies investigating the persistence and e... Read More about Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review..

Baseline characteristics of patients registering to the British Association of Dermatologists Biologics and Immunomodulators Register stratified by duration of psoriasis at the time of registration (2019)
Journal Article
Reid, C., Mason, K. J., Esse, S., McElhone, K., Lunt, M., Cordingley, L., …Warren, R. B. (2019). Baseline characteristics of patients registering to the British Association of Dermatologists Biologics and Immunomodulators Register stratified by duration of psoriasis at the time of registration. British Journal of Dermatology, 181, 47

227 Real-world drug discontinuation of acitretin (ACI), ciclosporin (CsA), fumaric acid esters (FAE) and methotrexate (MTX) in patients with moderate-severe psoriasis (2019)
Journal Article
Mason, K. (2019). 227 Real-world drug discontinuation of acitretin (ACI), ciclosporin (CsA), fumaric acid esters (FAE) and methotrexate (MTX) in patients with moderate-severe psoriasis. Journal of Investigative Dermatology, 139(5), S39. https://doi.org/10.1016/j.jid.2019.03.303

Real-world discontinuation of ACI, CsA, FAE and MTX in patients with moderate-severe psoriasis is poorly characterised. The aim of this study was to determine whether treatment history affects the discontinuation rates of these therapies. The British... Read More about 227 Real-world drug discontinuation of acitretin (ACI), ciclosporin (CsA), fumaric acid esters (FAE) and methotrexate (MTX) in patients with moderate-severe psoriasis.

Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. (2019)
Journal Article
Warren, R., Marsden, A., Tomenson, B., Mason, K., Soliman, M., Burden, A., …Smith, C. (in press). Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 180(5), 1069 - 1076. https://doi.org/10.1111/bjd.16776

BACKGROUND: Biologic therapies have revolutionized the treatment of moderate-to-severe psoriasis. However, for reasons largely unknown, many patients do not respond or lose response to these drugs. OBJECTIVES: To evaluate demographic, social and clin... Read More about Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study..

Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy (2019)
Journal Article
Yiu, Z., Sorbe, C., Lunt, M., Rustenbach, S., Kühl, L., Augustin, M., …Owen, C. M. (2019). Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. British Journal of Dermatology, 180(4), 894 -901. https://doi.org/10.1111/bjd.17421

BACKGROUND: Patients with psoriasis are often concerned about the risk of serious infection associated with systemic psoriasis treatments. OBJECTIVES: To develop and externally validate a prediction model for serious infection in patients with psoria... Read More about Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy.

Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). (2019)
Journal Article
Yiu, Z., Ashcroft, D., Evans, I., McElhone, K., Lunt, M., Smith, C., …Mason, K. (2019). Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology, 180(2), 329 - 337. https://doi.org/10.1111/bjd.17036

BACKGROUND: Patients with psoriasis and clinicians are concerned that infliximab may be associated with a risk of serious infections. OBJECTIVES: To compare the risk of serious infections associated with infliximab in patients with chronic plaque pso... Read More about Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR)..